Organization
Pfizer Inc., New York, United States of America
1 abstract
Abstract
ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALSOrg: Sorbonne Université, INSERM, AP-HP Hospital Saint Antoine, Paris, France, Altoona Center for Clinical Research, Duncansville, United States of America, Northwestern University Feinberg School of Medicine, Chicago, United States of America, Pfizer Inc., Groton, United States of America, Pfizer Inc., New York, United States of America,